Skip to main content

Table 1 Patient characteristics

From: Randomized phase II study comparing the efficacy and safety of SOX versus mFOLFOX6 as neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer (KSCC1301)

Characteristics SOX arm
n=53 (%)
mFOLFOX6 arm
n=50 (%)
p-value
Age (years)
 Median (range) 63 (37–79) 64 (36–79) 0.3440
Sex
 Male 44 (83.0) 40 (80.0) 0.6930
 Female 9 (17.0) 10 (20.0)  
Performance status (ECOG)
 0 53 (100.0) 48 (96.0) 0.2332
 1 0 (0.0) 2 (4.0)  
Depth of wall invasion
 T3 39 (73.6) 37 (74.0) 0.9618
 T4 14 (26.4) 13 (26.0)  
Lymph node metastasis
 N0 20 (37.7) 16 (32.0) 0.6317
 N1 20 (37.7) 20 (40.0)  
 N2 13 (24.5) 12 (24.0)  
 N3a 0 (0.0) 2 (4.0)  
RAS status
 Unexamined 37 (70.0) 36 (72.0) 0.5945
 Wild 8 (15.1) 11 (22.0)  
 Mutant 8 (15.1) 3 (6.0)  
Past illness/comorbidity
 Yes 23 (43.4) 23 (46.0) 1.0000
 Cerebral infarction 2 (3.8) 3 (6.0)  
 Myocardial infarction 1 (1.9) 0 (0.0)  
 Hypertension 15 (28.3) 14 (28.0)  
 Diabetes 8 (15.1) 8 (16.0)  
 Others 11 (20.8) 11 (22.0)  
  1. aLymph node in the inferior mesenteric artery region,
  2. ECOG: Eastern Cooperative Oncology Group, SOX: S-1 and oxaliplatin, mFOLFOX6: folinic acid, 5-FU, and oxaliplatin